At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 137 enrolled
Drug / intervention
Tozorakimab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)
In Brief
A Phase 2 clinical trial evaluating Tozorakimab and Placebo for Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis. Completed, enrolled 137 participants across 90 sites in 15 countries.
Detailed Summary
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Canada, Czechia, Denmark, Germany, Hungary, Israel, Netherlands, New Zealand, Poland, South Africa, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartDec 2020
Primary CompletionMay 2023
Study CompletionNov 2023
TodayJul 2026
First PostedNov 16, 2020
Enrollment StartDec 14, 2020
Primary CompletionMay 30, 2023
Study CompletionNov 13, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.6 years ago
Interventions
Tozorakimabdrug
Participants will receive SC injection of tozorakimab as stated in arm description.
Placeboother
Participants will receive SC injection of placebo as stated in arm description.